A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

NCT04547907 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

688

Enrollment

OTHER_GOV

Sponsor class

Conditions

Breast Cancer,HER2-positive

Interventions

DRUG: Nab-paclitaxel+ trastuzumab+ patuzumab
DRUG: Docetaxel+ carboplatin+ trastuzumab + patuzumab

Sponsor

Henan Cancer Hospital